KEGG   DRUG: Lacosamide
Entry
D07299                      Drug                                   
Name
Lacosamide (JAN/USAN/INN);
Erlosamide;
Vimpat (TN)
Product
  Generic
LACOSAMIDE (ANI Pharmaceuticals), LACOSAMIDE (Alembic Pharmaceuticals Limited), LACOSAMIDE (Alembic Pharmaceuticals), LACOSAMIDE (American Health Packaging), LACOSAMIDE (Amneal Pharmaceuticals LLC), LACOSAMIDE (Amneal Pharmaceuticals of New York LLC), LACOSAMIDE (Ascend Laboratories), LACOSAMIDE (Aurobindo Pharma Limited), LACOSAMIDE (Aurobindo Pharma Limited), LACOSAMIDE (AvKARE), LACOSAMIDE (Breckenridge Pharmaceutical), LACOSAMIDE (Camber Pharmaceuticals), LACOSAMIDE (Camber Pharmaceuticals), LACOSAMIDE (Camber Pharmaceuticals), LACOSAMIDE (Florida Pharmaceutical Products), LACOSAMIDE (Fosun Pharma USA), LACOSAMIDE (Fresenius Kabi USA), LACOSAMIDE (Gland Pharma Limited), LACOSAMIDE (Glenmark Pharmaceuticals Inc. USA), LACOSAMIDE (Golden State Medical Supply), LACOSAMIDE (Indoco Remedies Limited), LACOSAMIDE (Indoco Remedies Limited), LACOSAMIDE (Leading Pharma), LACOSAMIDE (MSN LABORATORIES PRIVATE LIMITED), LACOSAMIDE (Major Pharmaceuticals), LACOSAMIDE (NorthStar RxLLC), LACOSAMIDE (Northstar Rx LLC.), LACOSAMIDE (Novadoz Pharmaceuticals LLC), LACOSAMIDE (Novadoz Pharmaceuticals LLC), LACOSAMIDE (PAI Holdings), LACOSAMIDE (Sagent Pharmaceuticals), LACOSAMIDE (ScieGen Pharmaceuticals), LACOSAMIDE (Sun Pharmaceutical Industries), LACOSAMIDE (Tris Pharma), LACOSAMIDE (Virtus Pharmaceuticals), LACOSAMIDE (Westminster Pharmaceuticals), LACOSAMIDE (XLCare Pharmaceuticals), LACOSAMIDE (Zydus Lifesciences Limited), LACOSAMIDE (Zydus Pharmaceuticals USA), LACOSAMIDE (Zydus Pharmaceuticals USA), LACOSAMIDE ORAL SOLUTION (Apotex Corp.), LACOSAMIDE ORAL SOLUTION (Ascend Laboratories)
Formula
C13H18N2O3
Exact mass
250.1317
Mol weight
250.2936
Structure
Class
Neuropsychiatric agent
 DG03199  Antiepileptic agent
Metabolizing enzyme substrate
 DG01642  CYP2C9 substrate
 DG01639  CYP2C19 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01933  CYP2C19 inhibitor
Remark
Therapeutic category: 1139
ATC code: N03AX18
Product: D07299<JP/US>
Efficacy
Antiepileptic, Pain relief (neuropathic)
Comment
Treatment of epilepsy and neuropathic pain
Target
SCN3A [HSA:6328] [KO:K04836]
SCN9A [HSA:6335] [KO:K04841]
SCN10A [HSA:6336] [KO:K04842]
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP2C9 [HSA:1559], CYP2C19 [HSA:1557]
Interaction
CYP inhibition: CYP2C19 [HSA:1557]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N03 ANTIEPILEPTICS
   N03A ANTIEPILEPTICS
    N03AX Other antiepileptics
     N03AX18 Lacosamide
      D07299  Lacosamide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Anticonvulsants
  Sodium Channel Agents
   Lacosamide
    D07299  Lacosamide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   113  Antiepileptics
    1139  Others
     D07299  Lacosamide (JAN/USAN/INN)
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG03199  Antiepileptic agent
   D07299  Lacosamide
 Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   D07299  Lacosamide
  DG01639  CYP2C19 substrate
   D07299  Lacosamide
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D07299  Lacosamide
 Metabolizing enzyme inhibitor
  DG01933  CYP2C19 inhibitor
   D07299  Lacosamide
Drug classes [BR:br08332]
 Neuropsychiatric agent
  DG03199  Antiepileptic agent
   D07299  Lacosamide
Target-based classification of drugs [BR:br08310]
 Ion channels
  Voltage-gated ion channels
   Sodium channels
    SCN3A
     D07299  Lacosamide (JAN/USAN/INN) <JP/US>
    SCN9A
     D07299  Lacosamide (JAN/USAN/INN) <JP/US>
    SCN10A
     D07299  Lacosamide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D07299
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D07299
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D07299
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D07299
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D07299
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D07299
Other DBs
CAS: 175481-36-4
PubChem: 51091636
PDB-CCD: LQO[PDBj]
LigandBox: D07299
LinkDB
KCF data

ATOM        18
            1   C8y C    21.1332  -17.9117
            2   C1b C    22.3451  -17.2121
            3   N1b N    23.5571  -17.9117
            4   C5a C    24.7689  -17.2121
            5   C1c C    25.9808  -17.9117
            6   C1b C    27.1927  -17.2121
            7   O2a O    28.4046  -17.9117
            8   C8x C    19.9214  -17.2121
            9   C8x C    18.7094  -17.9117
            10  C8x C    18.7094  -19.3111
            11  C8x C    19.9214  -20.0108
            12  C8x C    21.1332  -19.3111
            13  O5a O    24.7689  -15.8127
            14  N1b N    25.9808  -19.3110
            15  C1a C    29.6205  -17.2098
            16  C5a C    24.7564  -20.0179
            17  C1a C    23.5627  -19.3285
            18  O5a O    24.7562  -21.4198
BOND        18
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     6   7 1
            7     1   8 2
            8     8   9 1
            9     9  10 2
            10   10  11 1
            11   11  12 2
            12    1  12 1
            13    4  13 2
            14    5  14 1 #Up
            15    7  15 1
            16   14  16 1
            17   16  17 1
            18   16  18 2

» Japanese version   » Back

DBGET integrated database retrieval system